Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genome-wide association study of patient-rated and clinician-rated global impression of severity during antipsychotic treatment.

Pharmacogenetics and genomics - 1 Feb 2013

Clark Shaunna L, Souza Renan P, Adkins Daniel E, Aberg Karolina, Bukszár József, McClay Joseph L, Sullivan Patrick F, van den Oord Edwin J C G

Abstract excerpt

OBJECTIVE: To examine the unique and congruent findings between multiple raters in a genome-wide association study (GWAS) in the context of understanding individual differences in treatment response during antipsychotic therapy for schizophrenia. MATERIALS AND METHODS: We performed GWAS to search for genetic variation affecting treatment response. The analysis sample included 738 patients with schizophrenia,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antipsychotic Agents
Share to Biomarkers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genome-Wide Association Study

Share to Genotype

Share to Pharmacogenetics

Share to Polymorphism, Single Nucleotide

Share to Prognosis

Share to Schizophrenia

Source

Open in PubMed Open full text

Identifiers

PMID: 23241943
DOI: 10.1097/FPC.0b013e32835ca260
PMCID: PMC3922978

Genes

PPA2
TJP1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genome-wide association study of patient-rated and clinician-rated global impression of severity during antipsychotic treatment.PMID 23241943Read ↗

Schizophrenia Polygenic Risk Score as a Predictor of Antipsychotic Efficacy in First-Episode PsychosisSemantic proximity Read ↗

Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics.Semantic proximity Read ↗

Delineating significant genome-wide associations of variants with antipsychotic and antidepressant treatment response: implications for clinical pharmacogenomics.Semantic proximity Read ↗

Genome-wide association analyses of symptom severity among clozapine-treated patients with schizophrenia spectrum disordersSemantic proximity Read ↗

Genome-wide association analyses of symptom severity among clozapine-treated patients with schizophrenia spectrum disorderSemantic proximity Read ↗

Toward understanding genetic risk for differential antipsychotic response in individuals with schizophreniaSemantic proximity Read ↗

Prediction of antipsychotics efficacy based on a polygenic risk score: a real-world cohort studySemantic proximity Read ↗

Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia.Semantic proximity Read ↗

Pharmacogenetics and outcome with antipsychotic drugsSemantic proximity Read ↗

The identification of novel genetic variants associated with antipsychotic treatment response outcomes in first-episode schizophrenia patients.Semantic proximity Read ↗

Five novel loci associated with antipsychotic treatment response in patients with schizophrenia: a genome-wide association study.Semantic proximity Read ↗

Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.